Alexion Announces Presentations at ASN 2015, Including a Long-Term Follow-Up Study of SolirisÂ® (eculizumab) for the Prevention of Thrombotic Microangiopathy (TMA) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)